ACMSY

AccuStem Sciences Limited, founded in 2020 and headquartered in London, United Kingdom, focuses on providing diagnostic assays that utilize genomic signatures. These tests are developed to forecast the probability of both short-term and long-term relapse of ER+/HER2 breast cancer in individuals with an early-stage diagnosis.